Cellular response and molecular mechanism of antitumor activity by leinamycin in MiaPaCa human pancreatic cancer cells

Anti-Cancer Drugs

Volumn 15, Issue 7, 2004, Pages 689-696

  Bassett, Stephen ^a   Urrabaz, Rheanna ^b   Sun, Daekyu ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

DNA damage; Flow cytometry; Leinamycin; MiaPaCa cell

Indexed keywords

CHECKPOINT KINASE 2; DNA FRAGMENT; LEINAMYCIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TELOMERASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DISRUPTION; CONTROLLED STUDY; DNA ADDUCT; DNA ALKYLATION; DNA DAMAGE; DNA REPLICATION; DNA STRAND BREAKAGE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; EVALUATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MOLECULAR MECHANICS; OBSERVATION; OXIDATION; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA, NEOPLASM; DOWN-REGULATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; LACTAMS; MACROLIDES; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TELOMERASE; THIAZOLES; THIONES;

EID: 4143071365     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000136886.72917.6f     Document Type: Article

References (35)

1. Hara M, Asano K, Kawamoto I, Takiguchi T, Katsumata S, Takahashi K, et al. Leinamycin, a new antitumor antibiotic from Streptomyces: producing organism, fermentation and isolation. J Antibiot (Tokyo) 1989; 42: 1768-1774.
2. Hara M, Saitoh Y, Nakano H. DNA strand scission by the novel antitumor antibiotic leinamycin. Biochemistry 1990; 29:5676-5681.
3. Breydo L, Zang H, Mitra K, Gates KS. Thiol-independent DNA alkylation by leinamycin. J Am Chem Soc 2001; 123:2060-2061.
4. Breydo L, Gates KS. Activation of leinamycin by thiols: a theoretical study. J Org Chem 2002; 67:9054-9060.
5. Gates KS. Mechanisms of DNA damage by leinamycin. Chem Res Toxicol 2000; 13:953-956.
6. Behroozi SJ, Kim W, Dannaldson J, Gates KS. 1,2-Dithiolan-3-one 1-oxides: a class of thiol-activated DNA-cleaving agents that are structurally related to the natural product leinamycin. Biochemistry 1996; 35:1768-1774.
7. Kanda Y, Ashizawa T, Saitoh Y, Saito H, Gomi K, Okabe M. Synthesis and antitumor activity of leinamycin derivatives: modifications of C-8 hydroxy and C-9 keto groups. Bioorg Med Chem Lett 1998; 8:909-912.
8. Kanda Y, Ashizawa T, Kakita S, Takahashi Y, Kono M, Yoshida M, et al. Synthesis and antitumor activity of novel thioester derivatives of leinamycin. J Med Chem 1999; 42:1330-1332.
9. Ashizawa T, Kawashima K, Kanda Y, Gomi K, Okabe M, Ueda K, et al. Antitumor activity of KF22678, a novel thioester derivative of leinamycin. Anticancer Drugs 1999; 10:829-836.
10. Kanda Y, Ashizawa T, Kawashima K, Ikeda S, Tamaoki T. Synthesis and antitumor activity of novel C-8 ester derivatives of leinamycin. Bioorg Med Chem Lett 2003; 13:455-458.
11. Chatterji T, Kizil M, Keerthi K, Chowdhury G, Pospisil T, Gates KS. Small molecules that mimic the thiol-triggered alkylating properties seen in the natural product leinamycin. J Am Chem Soc 2003; 125:4996-4997.
12. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
13. Sun D, Hurley LH, Von Hoff DD. Telomerase assay using biotinylated-primer extension and magnetic separation of the products. Biotechniques 1998; 25:1046-1051.
14. Darzynkiewicz Z, Bedner E, Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol 2001; 38:179-193.
15. Kunifuji Y, Gotoh S, Abe T, Miura M, Karasaki Y. Down-regulation of telomerase activity by anticancer drugs in human ovarian cancer cells. Anticancer Drugs 2002; 13:595-598.
16. Faraoni I, Graziani G, Turriziani M, Masci G, Mezzetti M, Testori A, et al. Suppression of telomerase activity as an indicator of drug-induced cytotoxicity against cancer cells: in vitro studies with fresh human tumor samples. Lab Invest 1999; 79:993-1005.
17. Kiyozuka Y, Yamamoto D, Yang J, Uemura Y, Senzaki H, Adachi S, et al. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells. Anticancer Res 2001; 20:203-212.
18. Asai A, Kiyozuka Y, Yoshida R, Fujii T, Hioki K, Tsubura A. Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Anticancer Res 1998; 18:1465-1472.
19. Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, Cowell JK. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 1998; 16:2243-2248.
20. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15:2177-196.
21. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 2000; 97:10389-10394.
22. Sun D, Urrabaz R, Buzello C, Nguyen M. Effects of cisplatin on expression of DNA ligases in MiaPaCa human pancreatic cancer cells. Biochem Biophys Res Commun 2002; 298:537-544.
23. Sun D, Urrabaz R, Buzello C, Nguyen M. Induction of DNA ligase I by 1-beta-d-arabinosylcytosine and aphidicolin in MiaPaCa human pancreatic cancer cells. Exp Cell Res 2002; 280:90-96.
24. Newton GL, Aguilera JA, Ward JF, Fahey RC. Effect of polyamine-induced compaction and aggregation of DNA on the formation of radiation-induced strand breaks: quantitative models for cellular radiation damage. Radiat Res 1997; 148:272-284.
25. Povirk LF, Wubter W, Kohnlein W, Hutchinson F. DNA double-strand breaks and alkali-labile bonds produced by bleomycin. Nucleic Acids Res 1977; 4:3573-3580.
26. Liu W, Christenson SD, Standage S, Shen B. Biosynthesis of the enediyne antitumor antibiotic C-1027. Science 2002; 297:1170-1173.
27. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40:2353-2362.
28. 2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82:749-755.
29. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 1993; 53:3186-3192.
30. Lowndes NF, Murguia JR. Sensing and responding to DNA damage. Curr Opin Genet Dev 2002; 10:17-25.
31. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-439.
32. Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, et al. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001; 154:913-922.
33. Greider CW. Telomeres, telomerase and senescence. BioEssays 1990; 12:363-369.
34. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev 1995; 5:249-255.
35. Opitz OG. The role of telomeres and telomerase in human cancer. Cancer Biol Ther 2003; 2:460-461.